肺気腫治療市場- 世界の産業規模、シェア、動向、機会、予測、治療別、流通チャネル別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

肺気腫治療の世界市場規模は2024年に44億7,000万米ドルとなり、予測期間には63億6,000万米ドルに達すると予測され、2030年までのCAGRは6.02%です。

世界の肺気腫治療市場は、医療技術の進歩や慢性呼吸器疾患に対する意識の高まりにより、着実な成長を遂げています。肺気腫は、喫煙や環境汚染物質と関連することが多い進行性の肺疾患であり、有病率が上昇していることから、効果的な治療オプションに対する需要が高まっています。製薬会社や医療機器会社は、長時間作用型気管支拡張薬、生物学的製剤、肺活量減少手術（LVRS）や気管支内弁移植術のような低侵襲手術など、革新的な治療法の開発に積極的に取り組んでいます。個別化治療戦略へのシフトは、疾患の重症度や治療に対する個々の反応に基づいて介入を調整することにより、患者の転帰を改善しています。携帯型酸素療法機器やデジタル呼吸モニタリングツールなどの在宅ヘルスケアソリューションの拡大は、疾病管理を強化し、市場の成長を支えています。

再生医療や遺伝子ベースの治療法の研究が進み、疾患修飾の可能性を探ることで、治療の展望が変わりつつあります。標的を絞った抗炎症療法や再生療法の開発は、疾患の進行を遅らせ、肺機能を改善することを目的としています。バイオ製薬企業は、新たな治療手段としてモノクローナル抗体と幹細胞療法に注目しています。診断と疾患モニタリングにおける人工知能（AI）の統合は、早期発見とより的確な介入を可能にし、合併症を減少させる。各社は、治療効果の向上と副作用の軽減に重点を置き、提携や臨床試験を通じてパイプラインの拡充に投資しています。気管支拡張薬、抗炎症薬、肺リハビリテーションプログラムを組み込んだ併用療法が重視され、包括的な疾患管理が強化され、製品イノベーションが推進されています。

主な市場促進要因

医療技術の進歩

主な市場課題

高い治療費

主な市場動向

低侵襲手術の採用

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の肺気腫治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療別（禁煙、気管支拡張薬、ステロイド、ロイコトリエン修飾薬、酸素補給、抗生物質、遺伝子治療、手術移植、その他の治療）
  • 流通チャネル別（病院薬局、小売薬局、その他の流通チャネル）
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 治療別
  • 流通チャネル別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋地域の肺気腫治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療別
  • 流通チャネル別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の肺気腫治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の肺気腫治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の肺気腫治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの肺気腫治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の肺気腫治療市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Icure Pharmaceuticals Inc.
• AstraZeneca Plc.
• Teva Pharmaceuticals Industries Ltd.
• Novartis AG
• GlaxoSmithKline Plc.
• Hikma Pharmaceuticals Plc
• Boehringer Ingelheim International GmbH
• Mylan N.V.
• Pfizer Inc.
• Orion Corporation

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Emphysema Treatment Market was valued at USD 4.47 Billion in 2024 and is expected to reach USD 6.36 Billion in the forecast period with a CAGR of 6.02% through 2030. The global emphysema treatment market is witnessing steady growth, driven by advancements in medical technology and increasing awareness about chronic respiratory diseases. Emphysema, a progressive lung condition often linked to smoking and environmental pollutants, has seen a rise in prevalence, prompting demand for effective treatment options. Pharmaceutical and medical device companies are actively developing innovative therapies, including long-acting bronchodilators, biologics, and minimally invasive procedures like lung volume reduction surgery (LVRS) and endobronchial valve implantation. The shift toward personalized treatment strategies is improving patient outcomes by tailoring interventions based on disease severity and individual response to therapy. The expansion of home healthcare solutions, including portable oxygen therapy devices and digital respiratory monitoring tools, is enhancing disease management and supporting market growth.

Ongoing research into regenerative medicine and gene-based therapies is transforming the treatment landscape by exploring potential disease-modifying solutions. The development of targeted anti-inflammatory and regenerative therapies aims to slow disease progression and improve lung function. Biopharmaceutical companies are focusing on monoclonal antibodies and stem cell therapies as emerging treatment avenues. The integration of artificial intelligence (AI) in diagnostics and disease monitoring is enabling early detection and more precise intervention, reducing complications. Companies are investing in pipeline expansion through collaborations and clinical trials, with an emphasis on improving treatment efficacy and reducing adverse effects. The emphasis on combination therapies, incorporating bronchodilators, anti-inflammatory drugs, and pulmonary rehabilitation programs, is enhancing comprehensive disease management and driving product innovation.

Key Market Drivers

Advancements in Medical Technology

Advancements in medical technology are significantly enhancing the global emphysema treatment market. Emphysema, a debilitating form of chronic obstructive pulmonary disease (COPD), has historically been challenging to manage. However, recent technological breakthroughs are transforming emphysema care.

Minimally invasive procedures, such as bronchoscopic lung volume reduction (BLVR), have become pivotal in emphysema treatment. BLVR involves the insertion of devices like endobronchial valves to occlude diseased lung regions, thereby improving respiratory function. Clinical studies have demonstrated that BLVR can enhance lung performance and quality of life in selected patients. For instance, research indicates that BLVR procedures have shown promising outcomes in improving lung function and exercise capacity among patients with advanced emphysema.

The development of biologics and targeted therapies marks another significant advancement in emphysema management. These treatments aim at specific molecular pathways that contribute to disease progression, potentially decelerating emphysema's advancement and enhancing pulmonary function. This targeted approach offers a more effective and less invasive alternative to traditional therapies.

Key Market Challenges

High Treatment Costs

High treatment costs are a significant barrier hindering the advancement of the Global Emphysema Treatment Market. Emphysema, a debilitating chronic obstructive pulmonary disease (COPD), affects millions of individuals worldwide, and managing this condition can be financially burdensome for both patients and healthcare systems.

The development of innovative emphysema treatments, such as bronchoscopic lung volume reduction (BLVR) procedures and targeted biologics, has offered new hope to patients by providing potentially more effective and less invasive options. However, these cutting-edge treatments often come with a hefty price tag.

For many emphysema patients, the high cost of treatment represents a substantial financial barrier. Coping with the financial burden of these therapies can be overwhelming, particularly for those without comprehensive health insurance coverage. High deductibles, copayments, and out-of-pocket expenses can strain patients' finances and limit their access to essential treatments.

Additionally, emphysema is a chronic condition that often requires ongoing care, including medications, regular check-ups, and pulmonary rehabilitation. These long-term expenses further compound the financial challenges faced by patients, potentially forcing them to make difficult choices between healthcare and other essential needs.

The burden of high treatment costs also extends to healthcare systems and governments. As the prevalence of emphysema continues to rise, the strain on healthcare budgets becomes more pronounced. The cost of providing advanced treatments and therapies can lead to allocation challenges, diverting resources from other critical healthcare needs.

Key Market Trends

Adoption of Minimally Invasive Procedures

The adoption of minimally invasive procedures is playing a pivotal role in boosting the Global Emphysema Treatment Market. Emphysema, a progressive lung condition characterized by the destruction of lung tissue, has traditionally been associated with invasive surgical treatments or long-term medication. However, recent advancements in medical technology have led to the development and widespread adoption of minimally invasive procedures, offering a paradigm shift in the way emphysema is treated.

One of the most significant contributors to the growth of minimally invasive procedures is the emergence of bronchoscopic lung volume reduction (BLVR) techniques. BLVR involves the insertion of small devices or materials into the airways to block or reduce airflow to damaged lung areas. This procedure aims to improve lung function and alleviate symptoms without the need for open surgery. Patients benefit from shorter hospital stays, faster recovery times, and reduced risk of complications compared to traditional surgical approaches.

The appeal of minimally invasive procedures goes beyond their effectiveness; it lies in their patient-centric approach. Patients are more inclined to opt for less invasive treatments that offer quicker recovery times and a lower risk of complications. As a result, healthcare providers increasingly recommend and perform BLVR and other minimally invasive procedures, meeting the preferences and expectations of patients.

Moreover, the adoption of minimally invasive procedures aligns with the broader trend in healthcare toward value-based care and cost-effectiveness. These procedures typically lead to reduced healthcare costs due to shorter hospital stays and less post-operative care, benefiting both patients and healthcare systems.

Key Market Players

• Icure Pharmaceuticals Inc.
• AstraZeneca Plc.
• Teva Pharmaceuticals Industries Ltd.
• Novartis AG
• GlaxoSmithKline Plc.
• Hikma Pharmaceuticals Plc
• Boehringer Ingelheim International GmbH
• Mylan N.V.
• Pfizer Inc.
• Orion Corporation

Report Scope:

In this report, the Global Emphysema Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Emphysema Treatment Market, By Treatment:

• Smoking Cessation
• Bronchodilators
• Steroids
• Leukotriene Modifiers
• Supplemental Oxygen
• Antibiotics
• Gene Therapy
• Surgery Transplant
• Other Treatments

Emphysema Treatment Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels

Emphysema Treatment Market, By End-User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Emphysema Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Emphysema Treatment Market.

Available Customizations:

Global Emphysema Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Emphysema Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment (Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments)
  • 4.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
  • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Treatment
  • 4.3.2. By Distribution Channel
  • 4.3.3. By End-User
  • 4.3.4. By Region

5. Asia Pacific Emphysema Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment
  • 5.2.2. By Distribution Channel
  • 5.2.3. By End-User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Emphysema Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment
      • 5.3.1.2.2. By Distribution Channel
      • 5.3.1.2.3. By End-User
  • 5.3.2. India Emphysema Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment
      • 5.3.2.2.2. By Distribution Channel
      • 5.3.2.2.3. By End-User
  • 5.3.3. Australia Emphysema Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment
      • 5.3.3.2.2. By Distribution Channel
      • 5.3.3.2.3. By End-User
  • 5.3.4. Japan Emphysema Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment
      • 5.3.4.2.2. By Distribution Channel
      • 5.3.4.2.3. By End-User
  • 5.3.5. South Korea Emphysema Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment
      • 5.3.5.2.2. By Distribution Channel
      • 5.3.5.2.3. By End-User

6. Europe Emphysema Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Distribution Channel
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Emphysema Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Distribution Channel
      • 6.3.1.2.3. By End-User
  • 6.3.2. Germany Emphysema Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Distribution Channel
      • 6.3.2.2.3. By End-User
  • 6.3.3. Spain Emphysema Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Distribution Channel
      • 6.3.3.2.3. By End-User
  • 6.3.4. Italy Emphysema Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment
      • 6.3.4.2.2. By Distribution Channel
      • 6.3.4.2.3. By End-User
  • 6.3.5. United Kingdom Emphysema Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment
      • 6.3.5.2.2. By Distribution Channel
      • 6.3.5.2.3. By End-User

7. North America Emphysema Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Distribution Channel
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Emphysema Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Distribution Channel
      • 7.3.1.2.3. By End-User
  • 7.3.2. Mexico Emphysema Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Distribution Channel
      • 7.3.2.2.3. By End-User
  • 7.3.3. Canada Emphysema Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Distribution Channel
      • 7.3.3.2.3. By End-User

8. South America Emphysema Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Distribution Channel
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Emphysema Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Distribution Channel
      • 8.3.1.2.3. By End-User
  • 8.3.2. Argentina Emphysema Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Distribution Channel
      • 8.3.2.2.3. By End-User
  • 8.3.3. Colombia Emphysema Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Distribution Channel
      • 8.3.3.2.3. By End-User

9. Middle East and Africa Emphysema Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Distribution Channel
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Emphysema Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Distribution Channel
      • 9.3.1.2.3. By End-User
  • 9.3.2. Saudi Arabia Emphysema Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Distribution Channel
      • 9.3.2.2.3. By End-User
  • 9.3.3. UAE Emphysema Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Distribution Channel
      • 9.3.3.2.3. By End-User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Emphysema Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Icure Pharmaceuticals Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. AstraZeneca Plc.
• 14.3. Teva Pharmaceuticals Industries Ltd.
• 14.4. Novartis AG
• 14.5. GlaxoSmithKline Plc.
• 14.6. Hikma Pharmaceuticals Plc
• 14.7. Boehringer Ingelheim International GmbH
• 14.8. Mylan N.V.
• 14.9. Pfizer Inc.
• 14.10. Orion Corporation

15. Strategic Recommendations

16. About Us & Disclaimer